The guy who tanked Valeant has 'significantly' reduced his short position in the company
Citron Research's Andrew Left has "significantly" reduced his short position in Valeant Pharmaceuticals."Think about risk reward here," Left said in an interview with CNBC's Scott Wapner on Tuesday.
In the report, Citron alleged that Valeant had been using its relationship with Philidor - a specialty pharmacy that used to distribute Valeant products almost exclusively - to file fake invoices and make its revenue appear greater than it is.Valeant also purchased the option to buy Philidor for $100 million last December.
When Left's report went live Valeant's share price was at $142. On Tuesday it was at $85 - a 43% drop.Also since then, Valeant has severed ties with Philidor and announced that the pharmacy will be closed by the end of January 2016.So Left has to feel like a lot of his work is done.
- Infosys had a great year but CEO Salil Parekh expects the next one to be more than twice as good
- Infosys will buy back shares at ₹1,750 — more than what some analysts had expected
- Best broadband plans in India in 2021 – JioFiber, Airtel Xstream Fiber and ACT Fibernet
- IPL 2021: Royal Challengers Bangalore have beaten Sunrisers Hyderabad 7 out of 18 times they played each other
- Publicis Groupe consolidates Data Science, Programmatic and Media Tech with Zenith and Starcom, under a common leadership